ARS PHARMACEUTICALS
🇮🇳India
Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent Urticaria Flares
Phase 2
Completed
- Conditions
- Urticaria
- Interventions
- Drug: ARS-1Drug: Placebo
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- ARS Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05496465
- Locations
- 🇺🇸
Bernstein Clinical Research Center, LLC, Cincinnati, Ohio, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- ARS Pharmaceuticals, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT05363670
- Locations
- 🇺🇸
University of South Florida, Tampa, Florida, United States
🇺🇸Bernstein Clinical Research Center, LLC, Cincinnati, Ohio, United States
🇺🇸Institute for Asthma and Allergy, Chevy Chase, Maryland, United States
Pharmacokinetics of Adrenaline After Administration of ARS -1 in Subjects With Upper Respiratory Tract Infection
Phase 1
Completed
- Conditions
- Upper Respiratory Tract Infection
- Interventions
- Drug: ARS-1 with URTIDrug: ARS-1 without URTI
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2022-07-29
- Lead Sponsor
- ARS Pharmaceuticals, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT04930900
- Locations
- 🇦🇺
Anthony McGirr, Brookvale, New South Wales, Australia
© Copyright 2025. All Rights Reserved by MedPath